Other - Preclinical programs are underway exploring the potential utility of Zantrene as an anti- cancer agent across more than 100 cancer types. Early data from these programs suggests Zantrene may have broad utility across a wide range of cancer types.
The above was of interest and raises some questions…. Does RAC have the capacity to do this wide ranging preclinical study internally, or is it more likely being undertaken by parties external to RAC? Which parties would be undertaking this? Local or International? Pharma/Corporate or Academic Research? 100 is a
lot of different cancer types, will these include any brain cancers and paediatric cancers? Will the results form part of another important/high profile scientific paper? What kind of impact could this have for future cancer patients/potential market/of Zantreme?
Ann: December 2022 Preclinical & Clinical Programs Update, page-10
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
0.020(1.18%) |
Mkt cap ! $289.4M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.74 | $1.72 | $54.20K | 31.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6023 | $1.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 500 | 1 |
View Market Depth
| Last trade - 10.24am 25/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |